News for BioVie Inc. (BIVI)

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders

BioVie (BIVI) has initiated the Phase 2 ADDRESS-LC clinical trial aimed at testing bezisterim for alleviating neurological symptoms linked to long COVID. They h

BioVie (BIVI) has announced a virtual event taking place on Wednesday, May 28, 2025, at 12:00 PM ET. The session will feature esteemed medical professionals, in

CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. ( BIVI), (”œBioVie” or the ”œCompany”), a clinical-stage company developing innovative d

BioVie (BIVI) to host a virtual KOL event discussing the Phase 2 trial of bezisterim (NE3107) for Parkinson's treatment on May 28, 2025. The SUNRISE-PD

CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., ( BIVI) (”œBioVie” or the ”œCompany”) a clinical-stage company developing innovative dr

**media[617409]**

BioVie (BIVI) has unveiled its new Corporate Advisory Board, featuring a distinguished group of seven leaders with extensive achievements across various fields

The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardn

BioVie Inc. (BIVI) has commenced patient enrollment for its Phase 2 SUNRISE-PD clinical trial. This study aims to assess the safety and efficacy of bezisterim i

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated w

Sponsored by The Sustainable Green Team (OTC: SGTM), featuring Kevin Harrington - the ORIGINAL Shark from Shark Tank NEW YORK CITY, NEW YORK / ACC...

**media[578264]**

Vivani Medical, Inc. (NASDAQ: VANI) (”œVivani” or the ”œCompany”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting dru

BioVie (BIVI) filed to sell, read the latest filing here.

CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. ( BIVI), (”œBioVie” or the ”œCompany”), a clinical-stage company developing innovative

BioVie shareholders approve board nominees and equity plan expansion

Texas-based Digital Turbine, Inc. (APPS) is down over 38 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

**media[455419]**